Biopharma Daily Updates - 12/21/20

$XBI $149.85 (+1.5%) 📈


$BNTX (+2%) - European Commission (EC) has granted a conditional marketing authorization (CMA) to Pfizer and BioNTech for COMIRNATY


$ORTX (-5%) - Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)

$QURE(-16%) - uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program

$ZGNX (+1%) - The European Commission Approves Zogenix’s FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome


$AGIO (+28%) - Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties

$NK (+56%) - ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company[min]=

$GMDA (-1%) - Closed offering


*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.